Keith Regnante

Chief Financial Officer

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

Affiliation history

Recorded current and former roles; source labels appear when available.

Recorded roles and earnings-call appearances connecting this person to public companies.

KROS

CFO

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2025	Keros Therapeutics, Inc. (KROS)	Chief Financial Officer	$470,382	—	$464,640	—	$164,850	$14,000	$1,113,872
2024	Keros Therapeutics, Inc. (KROS)	Chief Financial Officer	$447,799	—	—	$1,633,436	$197,142	$13,800	$2,292,177
2023	Keros Therapeutics, Inc. (KROS)	Chief Financial Officer	$434,808	—	—	$1,561,306	$191,400	$9,900	$2,197,414
2021	Keros Therapeutics, Inc. (KROS)	Chief Financial Officer	$401,800	—	—	$2,444,315	$200,900	$540	$3,047,555
2020	Keros Therapeutics, Inc. (KROS)	Chief Financial Officer	$323,170	—	—	$1,901,352	$138,000	$521	$2,363,042

Earnings-call appearances and filed executive appointments or departures, newest first.